Association of macrolides with overall mortality and cardiac death among patients with various infections: A meta-analysis

European Journal of Internal Medicine

Volumn 28, Issue , 2016, Pages 32-37

  Li, Xiang ^a   Wang, Min ^a   Liu, Guiyang ^a   Ma, Jianli ^a   Li, Chuntong ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Cardiac death; Infection; Macrolides; Meta analysis; Mortality

Indexed keywords

MACROLIDE; ROXITHROMYCIN; ANTIINFECTIVE AGENT;

AGE; ANTIBIOTIC THERAPY; ARTICLE; CARDIOTOXICITY; HEART DEATH; HUMAN; INFECTION; META ANALYSIS; MORTALITY; OUTCOME ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; SYSTEMATIC REVIEW; ARRHYTHMIAS, CARDIAC; BACTERIAL INFECTIONS; CASE CONTROL STUDY; DEATH; PROTECTION; RISK FACTOR;

ANTI-BACTERIAL AGENTS; ARRHYTHMIAS, CARDIAC; BACTERIAL INFECTIONS; CASE-CONTROL STUDIES; DEATH; HUMANS; MACROLIDES; MORTALITY; PROTECTIVE FACTORS; RISK FACTORS;

EID: 84964255607     PISSN: 09536205     EISSN: 18790828     Source Type: Journal    
DOI: 10.1016/j.ejim.2015.09.009     Document Type: Article

References (26)

1. Sperryville VA. Antimicrobial therapy. Sanford guide to antimicrobial therapy. 43th edn. Antimicrobial Therapy Poc Press; 2013.
2. F. Bril, C.D. Gonzalez, and G.D. Girolamo Antimicrobial agents-associated with QT interval prolongation Curr Drug Saf 5 1 2010 85 92
3. FDA Drug Safety Communication. Azithromycin (Zithromax or Zmax) and the risk of potentially fatal heart rhythms; 2013. Database: figshare [Internet]. Accessed: http://www.fda.gov/drugs/drugsafety/ucm341822.html.
4. P.P. Gleason, T.P. Meehan, J.M. Fine, D.H. Galusha, and M.J. Fine Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia Arch Intern Med 159 21 1999 2562 2572
5. C.R. Frei, M.I. Restrepo, E.M. Mortensen, and D.S. Burgess Impact of guideline-concordant empiric antibiotic therapy in community-acquired pneumonia Am J Med 119 10 2006 865 871
6. E.M. Mortensen, E.A. Halm, M.J. Pugh, L.A. Copeland, M. Metersky, M.J. Fine, and et al. Association of azithromycin with mortality and cardiovascular events among older patients hospitalized with pneumonia JAMA 311 21 2014 2199 2208
7. W.A. Ray, K.T. Murray, K. Hall, P.G. Arbogast, and C.M. Stein Azithromycin and the risk of cardiovascular death N Engl J Med 366 20 2012 1881 1890
8. Schembri S, Williamson PA, Short PM, Singanayagam A, Akram A, Taylor J, et al. Cardiovascular events after clarithromycin use in lower respiratory tract infections: analysis of two prospective cohort, studies. BMJ.2013; 346: f1235.
9. H. Svanström, B. Pasternak, and A. Hviid Use of azithromycin and death from cardiovascular causes N Engl J Med 368 18 2013 1704 1712
10. Svanström H, Pasternak B, Hviid A. Use of clarithromycin and roxithromycin and risk of cardiac death: cohort study. BMJ.2014; 349: g4930.
11. F.W. Arnold, A.S. LaJoie, G.N. Brock, P. Peyrani, J. Rello, R. Menendez, and et al. Improving outcomes in elderly patients with community-acquired pneumonia by adhering to national guidelines: Community-Acquired Pneumonia Organization International cohort study results Arch Intern Med 169 16 2009 1515 1524
12. L. Asadi, D.T. Eurich, J.M. Gamble, J.K. Minhas-Sandhu, T.J. Marrie, and S.R. Majumdar Guideline adherence and macrolides reduced mortality in outpatients with pneumonia Respir Med 106 3 2012 451 458
13. R.B. Brown, P. Iannini, P. Gross, and M. Kunkel Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia: analysis of a hospital claims-made database Chest 123 5 2003 1503 1511
14. C.R. Frei, M.I. Restrepo, E.M. Mortensen, and D.S. Burgess Impact of guideline-concordant empiric antibiotic therapy in community-acquired pneumonia Am J Med 119 10 2006 865 871
15. G.A. Rao, J.R. Mann, A. Shoaibi, C.L. Bennett, G. Nahhas, S. Sutton, and et al. Azithromycin and levofloxacin use and increased risk of cardiac arrhythmia and death Ann. Fam. Med. 12 2 2014 121 127
16. J.C. Hancox, M. Hasnain, W.V. Vieweg, E.L. Crouse, and A. Baranchuk Azithromycin, cardiovascular risks, QTc interval prolongation, torsade de pointes, and regulatory issues: a narrative review based on the study of case reports Ther Adv Infect Dis 1 5 2013 155 165
17. P.A. Howard Azithromycin-induced proarrhythmia and cardiovascular death Ann Pharmacother 47 11 2013 1547 1551
18. C. Garcia-Vidal, N. Fernández-Sabé, J. Carratalà, V. Díaz, R. Verdaguer, J. Dorca, and et al. Early mortality in patients with community-acquired pneumonia: causes and risk factors Eur. Respir. J. 32 3 2008 733 739
19. F. Paganin, F. Lilienthal, A. Bourdin, N. Lugagne, F. Tixier, R. Génin, and et al. Severe community-acquired pneumonia: assessment of microbial aetiology as mortality factor Eur. Respir. J. 24 5 2004 779 785
20. M.I. Restrepo, E.M. Mortensen, G.W. Waterer, R.G. Wunderink, J.J. Coalson, and A. Anzueto Impact of macrolides therapy on mortality for patients with severe sepsis due to pneumonia Eur Respir J 33 1 2009 153 159
21. M. Restrepo, E. Mortensen, L. Copeland, B. Nakashima, M. Pugh, and A. Anzueto Macrolide therapy is associated with lower 30-day mortality in patients with non-pneumonia and pneumonia severe sepsis Eur. Respir. J. 38 Suppl. 55 2011 2554
22. A. Rodriguez, A. Mendia, J.M. Sirvent, F. Barcenilla, M.V. de la Torre-Prados, J. Sole-Violan, and et al. Combination antibiotic therapy improves survival in patients with community-acquired pneumonia and shock Crit Care Med 35 6 2007 1493 1498
23. P. Zarogoulidis, N. Papanas, I. Kioumis, E. Chatzaki, E. Maltezos, and K. Zarogoulidis Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases Eur J ClinPharmacol 68 5 2012 479 503
24. G.W. Amsden Anti-inflammatory effects of macrolides - an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions? J. Antimicrob. Chemother 55 1 2005 10 21
25. P. Spagnolo, L.M. Fabbri, and A. Bush Long-term macrolide treatment for chronic respiratory disease Eur. Respir. J. 42 1 2013 239 251
26. D.P. Healy Macrolide immunomodulation of chronic respiratory diseases Curr Infect Dis Rep 9 1 2007 7 13